Pulmonx Corporation (LUNG) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Pulmonx Corporation (LUNG) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
LUNG - Pulmonx Corporation
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$10.00
DETAILS
HIGH:
$20.00
LOW:
$2.50
MEDIAN:
$9.75
CONSENSUS:
$10.00
UPSIDE:
545.16%
Stock News
Pulmonx Corporation (LUNG) Q1 2026 Earnings Call Transcript
Pulmonx Corporation (LUNG) Q1 2026 Earnings Call Transcript
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.33 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.36 per share a year ago.
Pulmonx Reports First Quarter 2026 Financial Results
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2026 ended March 31, 2026.
Pulmonx to Present at the Bank of America Securities 2026 Health Care Conference
REDWOOD CITY, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12, 2026, at 8:15 AM PT / 11:15 AM ET.
Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026
REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Wednesday, April 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Pulmonx Corporation (NASDAQ:LUNG) Given Average Rating of “Hold” by Brokerages
Pulmonx Corporation (NASDAQ: LUNG - Get Free Report) has received an average recommendation of "Hold" from the eight research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.33 per share a year ago.
Pulmonx Corporation (LUNG) Q4 2025 Earnings Call Transcript
Pulmonx Corporation (LUNG) Q4 2025 Earnings Call Transcript
Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results
REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025.
Pulmonx Announces Closing of up to $60 Million Credit Facility
Refinancing Strengthens Capital Structure by Extending Debt Maturity and Providing Access to Additional Undrawn Capital Refinancing Strengthens Capital Structure by Extending Debt Maturity and Providing Access to Additional Undrawn Capital
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Reviewing Talkspace (NASDAQ:TALK) and Pulmonx (NASDAQ:LUNG)
Talkspace (NASDAQ: TALK - Get Free Report) and Pulmonx (NASDAQ: LUNG - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations. Profitability This table compares Talkspace and Pulmonx's net margins,
SOPHiA GENETICS (NASDAQ:SOPH) versus Pulmonx (NASDAQ:LUNG) Critical Comparison
SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) and Pulmonx (NASDAQ: LUNG - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership. Risk and Volatility SOPHiA GENETICS has a beta
Analyzing Pulmonx (NASDAQ:LUNG) and Privia Health Group (NASDAQ:PRVA)
Pulmonx (NASDAQ: LUNG - Get Free Report) and Privia Health Group (NASDAQ: PRVA - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability. Analyst Ratings This is a breakdown of current
Pulmonx (NASDAQ:LUNG) & Alternate Health (OTCMKTS:AHGIF) Critical Comparison
Alternate Health (OTCMKTS:AHGIF - Get Free Report) and Pulmonx (NASDAQ: LUNG - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings. Valuation and Earnings This table compares Alternate Health and
Price Targets
Pulmonx price target lowered to $4 from $8 at Lake Street
$4.00
(was $2.42)
Lake Street
Pulmonx downgraded to Neutral from Overweight at Piper Sandler
$2.50
(was $3.15)
Jason Bednar
·
Piper Sandler
Pulmonx price target lowered to $10 from $12 at Piper Sandler
$10.00
(was $6.79)
Jason Bednar
·
Piper Sandler
Pulmonx price target raised to $16 from $15 at Canaccord
$16.00
(was $7.42)
William Plovanic
·
Canaccord Genuity
Lake Street Capital Markets Starts Pulmonx Corp. (LUNG) at Buy
$12.00
(was $7.00)
Frank Takkinen
·
Loop Capital Markets
Morgan Stanley Maintains Equal-Weight on Pulmonx, Lowers Price Target to $9.5
$9.50
(was $7.88)
Morgan Stanley
Wells Fargo Maintains Equal-Weight on Pulmonx, Lowers Price Target to $6
$6.00
(was $6.22)
Wells Fargo
Citigroup Upgrades Pulmonx to Buy, Lowers Price Target to $10
$10.00
(was $5.88)
Citigroup
Stifel Maintains Buy on Pulmonx, Lowers Price Target to $20
$20.00
(was $16.37)
Stifel Nicolaus
Morgan Stanley Maintains Equal-Weight on Pulmonx, Lowers Price Target to $19
$19.00
(was $16.20)
Morgan Stanley